News Headlines

  1. Piramal Pharma Solutions Supports George Medicines In Developing Its New Drug For Hypertension, WIDAPLIK™ (telmisartan, amlodipine And indapamide) 8/28/2025

    George Medicines, a leading late-stage biopharma company, in partnership with Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635)developed WIDAPLIK, a new drug for treatment of hypertension in adult patients, including as initial treatment, to lower blood pressure.

  2. IQVIA And Flagship Pioneering Announce Strategic Collaboration To Accelerate The Development Of Breakthrough Life Sciences Companies 8/28/2025

    IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the bioplatform innovation company, today announced a strategic collaboration to accelerate the development of breakthrough life sciences companies.

  3. Asimov Announces Cell Line Development Partnership With Ottimo Pharma To Accelerate Cancer Immunotherapy's Path To Clinic 8/27/2025

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a cell line development partnership with Ottimo Pharma, a biopharmaceutical company developing first-in-class, one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of people living with cancer.

  4. Hengdian Group's Apeloa Pharmaceutical Uses Flow Chemistry For Sustainable Manufacturing 8/27/2025

    Hengdian Group’s pharmaceutical arm Apeloa is using Flow Chemistry, a safer and more environmentally-friendly manufacturing approach than traditional batch processing, to drive sustainability in the pharmaceutical industry.

  5. Digital Twin Technology With AI To Boost Efficiency And Reliability In Pharmaceutical Manufacturing 8/27/2025

    Pharmaceutical manufacturing demands consistency, high precision, and continuous improvement to ensure the safety and quality of medicines. The new platform automates the development of digital twins, which are virtual replicas of production lines, to optimise plant operations, detect anomalies early, and support data-driven decision-making.

  6. Northwest Biotherapeutics Announces Agreement To Acquire Advent BioServices Ltd. 8/27/2025

    Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into an agreement to acquire Advent BioServices Ltd. from its owner, Toucan Holdings LLC.

  7. BioArctic And Novartis Sign An Option, Collaboration And License Agreement Using BrainTransporter™ For An Upfront Payment Of USD 30 Million Plus Additional Potential Milestones And Royalties 8/26/2025

    BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a potential new treatment combining BioArctic's proprietary BrainTransporter technology with an undisclosed target in neurodegeneration. As part of the initial research collaboration, BioArctic will receive USD 30 million in upfront payment.

  8. Immuneering Announces Clinical Supply Agreement With Lilly To Evaluate Atebimetinib In Combination With Olomorasib 8/25/2025

    Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982).

  9. AbbVie To Acquire Gilgamesh Pharmaceuticals' Bretisilocin, A Novel, Investigational Therapy For Major Depressive Disorder, Expanding Psychiatry Pipeline 8/25/2025

    AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals Inc. ("Gilgamesh") today announced a definitive agreement under which AbbVie will acquire Gilgamesh's lead investigational candidate, currently in clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

  10. Adva Biotechnology And Autolomous Announce Collaboration To Co-Lead The Digital Pioneer Program For Scalable Autologous Cell Therapy Manufacturing 8/25/2025

    Adva Biotechnology Ltd. and Autolomous Ltd. have announced a strategic collaboration to co-lead the Digital Pioneer Program, an early adopter initiative focused on digitising, decentralising, and scaling out autologous cell therapy manufacturing.